Clinical Trial Search

Primary: Mean Percentage Change in Symptom Severity at 6 Weeks Compared to Baseline, Using the Patient Completed Zurich Claudication Questionnaire for Symptom Severity — -29.7…

Primary: Change in Forced Expiratory Volume in 1 Sec (FEV1) Measured in L/Sec — 19.8; 55.2 L/sec

Primary: The Number of Participants Who Responded to the Conversion to Mycophenolate Sodium (EC-MPS) Therapy — 123; 109; 74; 88 Participants

Primary: In-stent Late Loss (LL) — 0.052; 0.238 millimeters

Primary: Changes in Small Dense Low-density Lipoprotein Cholesterol (sdLDL-C) Levels — -42; -46 sdLDL-C, mg/dL

Primary: Number of Participants With Fever Post Dose 1 (Days 1-8), Defined as an Axillary Temperature ≥ 101°F (38.3°C). — 4; 1 participants

Primary: Change From Baseline in the Total Blepharoconjunctivitis Grade. — -11.41; -11.23; -10.68; -10.30 Score on a scale

Primary: Post-operative Wound Drainage. — 892.5; 762.5; 565; 590 ml — p=0.704

Primary: Percentage of Participants Assessed for Pathological Complete Response (pCR) Plus Near Complete (npCR) in Primary Breast Tumor at Time of Definitive Surgery — 15.8; 50.0…

Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change

Primary: Percentage of Participants With Early Virologic Response — 80.8 percentage of participants

Primary: Best Corrected Visual Acuity — -0.075; -0.080; -0.081; 0.227 logMAR

Primary: Time to Treatment Failure (PI Comparison) — 16; 16; 40; 24 weeks — p=<0.01

Primary: Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate — 1.35; 2.12 Migraine attacks

Primary: Colonic Geometric Center at 24 Hours — 2.3; 1.8; 1.9; 2.3 Units on a scale — p=0.902